Status of CONRAD Research

Henry L. Gabelnick, Ph.D. Microbicides Trial Network Meeting March 26, 2007



CONRAD Planned Activities

- Continued development of preclinical models for safety and efficacy *in vitro*, small animals and nonhuman primates
- Clinical safety studies looking for biomarkers and animal correlations
- Combination product development based on UC-781, tenofovir and other proprietary compounds
- Evaluation of Q2 as an aid to achieve longer-acting, less coitally dependent formulations
- Development of alternative delivery systems such as sponges and mechanical barriers (eg, caps and diaphragms)



Collaboration with Field

Provide access to UC-781 and tenofovir
Coordinate activities
Provide technical assistance

Formulation
Manufacturing, packaging and labeling

FundingIP

